Table 4.
Predictors of HBV screeninga by cancer type
|
Predictor |
Hematologic malignancy (N = 3657) |
Solid tumorb (N =15,031) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| |
Screened |
Univariate logistic regression |
Multiple logistic regression OR |
Screened |
Univariate logistic regression |
Multiple logistic regression |
||||
| (N=2439) (66.7%) | OR (95% CI) | P value | (95% CI) | P value | (N=581) (3.9%) | OR (95% CI) | P value | OR (95% CI) | P value | |
| Age, years, mean (SD) |
52.5 (15.5) |
0.99 (0.99–1.0) |
0.005 |
0.99 (0.98–0.99) |
0.0001 |
52.4 (15.0) |
0.98 (0.98–0.99) |
<0.0001 |
0.98 (0.97–0.98) |
<0.0001 |
| Sex, no. (%) |
|
|
|
|
|
|
|
|
|
|
| Male |
1418/2133 (66.5) |
Ref. |
- |
- |
- |
297/5947 (5.0) |
Ref. |
- |
Ref. |
- |
| Female |
1021/1524 (67.0) |
1.0 (0.89–1.2) |
0.74 |
- |
- |
284/9084 (3.1) |
0.61 (0.52–0.73) |
<0.0001 |
0.58 (0.49–0.70) |
<0.0001 |
| Race/ethnicity, no. (%) |
|
|
|
|
|
|
|
|
|
|
| White |
1776/2645 (67.2) |
Ref. |
- |
Ref. |
- |
392/10,523 (3.7) |
Ref. |
- |
- |
- |
| Hispanic |
324/486 (66.7) |
0.98 (0.80–1.2) |
0.84 |
0.92 (0.75–1.1) |
0.45 |
78/1833 (4.3) |
1.1 (0.90–1.5) |
0.27 |
- |
- |
| Black |
196/333 (58.9) |
0.70 (0.56–0.88) |
0.003 |
0.69 (0.55–0.88) |
0.002 |
51/1759 (2.9) |
0.77 (0.57–1.0) |
0.09 |
- |
- |
| Asian |
41/50 (82.0) |
2.2 (1.1–4.6) |
0.03 |
2.0 (0.98–4.3) |
0.06 |
35/458 (7.6) |
2.1 (1.5–3.1) |
<0.0001 |
- |
- |
| Other |
102/143 (71.3) |
1.2 (0.8–1.8) |
0.23 |
1.0 (0.72–1.6) |
0.79 |
25/458 (5.5) |
1.5 (0.98–2.3) |
0.06 |
- |
- |
| Residence, no. (%) |
|
|
|
|
|
|
|
|
|
|
| US |
2332/3510 (66.4) |
Ref. |
- |
- |
- |
564/14,580 (3.9) |
Ref. |
- |
Ref. |
- |
| Outside US |
107/147(72.8) |
1.4 (0.93–2.0) |
0.11 |
- |
- |
17/451 (3.8) |
0.97 (0.59–1.6) |
0.92 |
0.51 (0.30–0.90) |
0.02 |
| HBV risk factor, no. (%) |
|
|
|
|
|
|
|
|
|
|
| No |
1683/2603 (64.7) |
Ref. |
- |
Ref. |
- |
321/10,694 (3.0) |
Ref. |
- |
Ref. |
|
| Yes |
756/1054 (71.7) |
1.4 (1.2–1.6) |
<0.0001 |
1.3 (1.1–1.5) |
0.001 |
260/4337 (6.0) |
2.1 (1.7–2.4) |
<0.0001 |
2.5 (2.1–3.0) |
<0.0001 |
| Chemotherapy type, no. (%) |
|
|
|
|
|
|
|
|
|
|
| Non-rituximab |
1191/1854 (64.2) |
Ref. |
- |
Ref. |
- |
469/14,857 (3.2) |
Ref. |
- |
Ref. |
- |
| Rituximab |
1248/1803 (69.2) |
1.2 (1.1–1.4) |
0.001 |
1.3 (1.2–1.5) |
<0.0001 |
112/174 (64.4) |
55.4 (40.1–76.6) |
<0.0001 |
62.0 (44.1–87.0) |
<0.0001 |
| Timing of first chemotherapyc |
|
|
|
|
|
|
|
|
|
|
| Period 1 |
1428/2312 (61.8) |
Ref. |
- |
Ref. |
- |
326/9521 (3.4) |
Ref. |
- |
Ref. |
- |
| Period 2 |
829/1101 (75.3) |
1.9 (1.6–2.2) |
<0.0001 |
2.0 (1.6–2.3) |
<0.0001 |
208/4602 (4.5) |
1.3 (1.1–1.6) |
0.001 |
1.3 (1.1–1.6) |
0.003 |
| Period 3 | 182/244 (74.6) | 1.8 (1.4–2.4) | <0.0001 | 1.9 (1.4–2.6) | <0.0001 | 47/908 (5.2) | 1.5 (1.1–2. 1) | 0.007 | 1.7 (1.2–2.3) | 0.003 |
Abbreviations: HBV hepatitis B virus, OR odds ratio, CI confidence interval, Ref., reference.
aHBV screening means that both hepatitis B surface antigen (HBsAg) test and antibody to hepatitis B core antigen (anti-HBc) test were ordered.
bExcludes patients with primary liver cancer.
cPeriod 1: 1/1/04 through 12/18/2008; period 2, 12/19/2008 through 9/30/2010; period 3, 10/1/2010 through 4/30/11.